Resultados: 38

    Interim recommendations of the advisory committee on immunization practices for use of Moderna and Pfizer-Biontech Covid-19 vaccines in children aged 6 months–5 years: United States, june 2022

    MMWR recomm. rep; 71 (26), 2022
    On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months–5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 va...

    Directrices para el tratamiento de las leishmaniasis en la región de las américas - 2 ed

    Las leishmaniasis son enfermedades infecciosas desatendidas de gran importancia en la Región de las Américas debido a su morbilidad, mortalidad y amplia distribución geográfica. De las tres formas clínicas principales, la cutánea es la más común y la visceral es la forma más grave, ya que puede ...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Moderna COVID-19 vaccine for children aged 6 months–5 years

    A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Moderna coronavirus disease 2019 (COVID-19) vaccine for children aged 6 months­-­­5 years was presented to the Advisory Committee for Immunization Practices (ACIP) on June 18,...

    Grading of recommendations, assessment, development, and evaluation (GRADE): Pfizer-BioNTech COVID-19 vaccine for children aged 6 months-4 Years

    Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine for children aged 6 months­–­­4 years was presented to the Advisory Committee for Immunization Practices (ACIP) on ...

    The Moderna COVID-19 vaccine’s local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients. Vaccine recipients reported higher rates of local reactions after dose 2 than dose 1. The frequency of local reactions was higher in the older age group (ages 2 to 5 years) than the younger ag...

    The advisory committee on immunization practices’ recommendation for use of Moderna COVID-19 vaccine in adults aged ≥18 years and considerations for extended intervals for administration of primary series doses of mRNA COVID-19 vaccines: United States, february 2022

    MMWR recomm. rep; 71 (11), 2022
    The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...

    ACIP update to the evidence to recommendations for a Pfizer-BioNTech COVID-19 booster in children ages 5-11 years

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 82 million cases and more than 998,000 COVID-19-associated deaths have...

    Guidelines for Perioperative Care in Elective Abdominal and Pelvic Surgery at Primary and Secondary Hospitals in Low–Middle-Income Countries (LMIC’s): Enhanced Recovery After Surgery (ERAS) Society Recommendation

    World j. sur; 46 (8), 2022
    This is the first Enhanced Recovery After Surgery (ERAS®) Society guideline for primary and secondary hospitals in low–middle-income countries (LMIC’s) for elective abdominal and gynecologic care. The ERAS LMIC Guidelines group was established by the ERAS® Society in collaboration with different re...

    ACIP update to the evidence to recommendations for a 2nd COVID-19 booster dose in adults ages 50 years and older and immunocompromised Individuals

    The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 80 million cases and more than 986,000 COVID-19-associated deaths have...

    Use of dexmedetomidine for sedation in mechanically ventilated adult ICU patients: a rapid practice guideline

    Intensive care med; (), 2022
    The aim of this Intensive Care Medicine Rapid Practice Guideline (ICM‑RPG) was to formulate evidence‑based guidance for the use of dexmedetomidine for sedation in invasively mechanically ventilated adults in the intensive care unit (ICU). We adhered to the methodology for trustworthy clinical practic...